Form 4: Ligand Pharmaceuticals Director Nancy Ryan Gray Sells Shares

Director Nancy Ryan Gray sold 934 shares of Ligand Pharmaceuticals (LGND) at a weighted-average price of $83.2049 on May 9, 2024.

Summary

• On May 9, 2024, Nancy Ryan Gray, a director of Ligand Pharmaceuticals Inc. (LGND), sold 934 shares of common stock.
• The sale was executed at a weighted-average price of $83.2049 per share.
• The prices for individual transactions ranged from $83.1100 to $83.2650.
• Following the transaction, Nancy Ryan Gray directly owns 5,633 shares of Ligand Pharmaceuticals.

Sentiment

Score: 5

Explanation: This is a neutral event. A director selling shares is not inherently positive or negative, but it's important for investors to be aware of such transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders. It is important to consider this transaction in the context of overall market conditions, company performance, and other insider trading activities.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies.
• Form 4 filings are standard practice and are used to ensure transparency and prevent illegal insider trading.
• The significance of this sale depends on its size relative to Gray's total holdings and the overall trading volume of LGND shares.
• Comparable companies in the pharmaceutical industry also have similar insider trading reporting requirements.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence.
• However, the impact is likely minimal unless the sale is part of a larger trend of insider selling.

Key Dates